CGTLive®’s Weekly Rewind – June 20, 2025

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys

In light of the patient’s death, Sarepta put a temporary hold on shipments of Elevidys for patients who are nonambulatory.

2. Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, on CAR-T Therapy JNJ-90014496's Safety Profile in R/R LBCL

The associate professor and the lymphoma stream lead at St Vincent’s Hospital, discussed data from a phase 1b trial for the CD19/CD20–directed bispecific CAR-T.

3. Beam’s Base-Editing HSC Therapy BEAM-101 Raises HbF Levels in Patients With Sickle Cell Disease

Beam Therapeutics’ team provided insight on data the company presented at EHA's 2025 Congress.

4. Omotayo Fasan, MRCP, DTM&H, MBBS, on Evaluating CAR-T GLPG5101 in R/R NHL

The head of the clinical development program at Galapagos discussed the design of GLPG5101 and touched on future plans for the therapy and other cell therapy products in the company's pipeline.

5. Alzheimer's & Brain Awareness Month 2025: Looking Back at Recent Progress in Cell and Gene Therapy

In honor of Alzheimer's & Brain Awareness Month, observed annually in June, we took a look back at recent news and insights in cell and gene therapy for Alzheimer disease and other dementias.